TO OPTIMIZE OUTCOMES IN EARLY NSCLC, IMPROVING BIOMARKER TESTING IS CRITICAL
“Despite the approval of numerous gene-targeted and [immune checkpoint inhibitor (ICI)] therapies, and the existence of guidelines advocating their use in metastatic and locally advanced [non-small cell lung cancer (NSCLC)], it...
Read More